Organisation paid for research Program year 2025 Source: CMS Open Payments

310 Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$354,848

204 payments

Through program year 2025, 310 Clinical Research is reported as receiving $354,848 in research payments, across 204 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$310,268	196
2024	Research	$44,580	8

Breakdown

Who paid Research payments · program years 2024–2025

Boehringer Ingelheim International GmbH $287,867 196 payments
Amgen Inc. $48,632 4 payments
Pfizer Inc. $18,350 4 payments

Studies the money was for Research payments · program years 2024–2025

A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $239,825 168 payments
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $46,177 26 payments
VOYAGER P3 AD Vaccine Study $24,366 2 payments
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $18,350 4 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $16,604 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $7,662 1 payment
BI 456906 in NASH F2/F3 - pivotal trial $1,698 1 payment
BI 456906 in NASH F4 - pivotal trial $167 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.